RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization

RADx-Rad 发现

基本信息

  • 批准号:
    10745886
  • 负责人:
  • 金额:
    $ 585.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-01-01 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Preparing SARS-CoV-2 testing data for reuse requires making the data syntactically and semantically equivalent. Standardization of terminologies and a common data model accomplish the former, while the latter is accomplished through understanding the data and making it comparable across RADx-rad awardees by benchmarking against known gold standards. The standardization of samples is as important as standardizing the data, particularly in the highly innovative RADx-rad program, where new technologies will be developed or optimized for deployment in various settings. Highly motivated RADx-rad awardees will receive advice on how their diagnostics compare to FDA-approved ones, with each other, how their diagnostic performs in independent testing, as well as how to ensure the tests are usable in real world settings. In collaboration with University of Texas Health Science Center at Houston, University of California San Diego researchers in informatics/data science and infectious diseases with ample experience in leading large consortia have designed a unique RADx-rad Consortium Data and Coordination Center (radCDCC). This center is based on three pillars: (1) effective administration and coordination among awardees, NIH, and other programs;; (2) innovative approaches and tools to collect and standardize data and metadata to promote findability, accessibility, interoperability and reuse (FAIR) for data sharing;; and (3) principled preparation of standardized samples with known quantities of viral loads, and standardized procedures for testing new diagnostics to allow comparison across tests and calibration of new technologies. Backed by sophisticated HIPAA-compliant cloud services, user friendly web-tools, and extensive support from UCSD’s facilities for computation and for clinical research, the radCDCC will interface with other RADx programs and other COVID-19 focused programs at NIH to ensure alignment of awardees, NIH and the public in the pursuit of effective, affordable, and deployable new technologies for testing
准备SARS-CoV-2测试数据以供重用需要使数据在语法和语义上等效。 术语的标准化和通用数据模型实现了前者,而后者是 通过理解数据并使其在RADx-rad获奖者之间具有可比性, 以已知的黄金标准为基准。样品的标准化与标准化同样重要 数据,特别是在高度创新的RADx-rad计划中,将开发新技术, 针对各种设置进行了优化。高度积极的RADx-rad获奖者将获得关于如何 他们的诊断与FDA批准的诊断进行比较,相互比较,他们的诊断在独立的 测试,以及如何确保测试在真实的世界设置中可用。与德克萨斯大学休斯顿健康科学中心合作,加州圣地亚哥大学的信息学/数据科学和传染病研究人员在领先的大型财团中拥有丰富的经验,他们设计了一个独特的RADx-rad财团数据和协调中心(radCDCC)。该中心基于三个支柱:(1)获奖者,NIH和其他计划之间的有效管理和协调;(2)创新方法和工具 收集数据和元数据并使之标准化,以促进数据的可查找性、可获取性、互操作性和重复使用 (3)原则性地制备具有已知数量病毒的标准化样品, 测试新诊断程序的标准化程序,以便在测试和校准之间进行比较 新科技的发展。以先进的符合HIPAA标准的云服务、用户友好的Web工具和 在加州大学圣地亚哥分校计算和临床研究设施的广泛支持下,radCDCC将与 与NIH的其他RADx项目和其他以COVID-19为重点的项目合作,以确保获奖者的一致性,NIH 和公众在追求有效的,负担得起的,可部署的新技术进行测试

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eliah S Aronoff-Spencer其他文献

Eliah S Aronoff-Spencer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eliah S Aronoff-Spencer', 18)}}的其他基金

RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization
RADx-Rad 发现
  • 批准号:
    10321007
  • 财政年份:
    2020
  • 资助金额:
    $ 585.3万
  • 项目类别:
RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization
RADx-Rad 发现
  • 批准号:
    10274180
  • 财政年份:
    2020
  • 资助金额:
    $ 585.3万
  • 项目类别:
RADx-Rad Discoveries & Data: Consortium Coordination Center Program Organization
RADx-Rad 发现
  • 批准号:
    10854683
  • 财政年份:
    2020
  • 资助金额:
    $ 585.3万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 585.3万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 585.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了